Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab Academic Article uri icon

Overview

MeSH Major

  • Nervous System Neoplasms

abstract

  • Combination treatment with ipilimumab and nivolumab may be an effective treatment in pituitary carcinoma. Clinical sequencing of pituitary tumors that have relapsed following treatment with conventional chemotherapy may identify the development of therapy-induced somatic hypermutation, which may be associated with treatment response to immunotherapy.

publication date

  • October 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1210/jc.2018-01347

PubMed ID

  • 30085142

Additional Document Info

start page

  • 3925

end page

  • 3930

volume

  • 103

number

  • 10